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safety pharmacology evaluations should indicate a low level of risk
associated with dosing and administration procedures, thereby
enhancing the rationale for investing in such a modality for the treat-
ment of OA.
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IMPACT OF KNEE OA ON MEETING PHYSICAL ACTIVITY GUIDELINES
D.K. White. Univ. of Delaware, Newark, DE, USA
Purpose: Physical activity has irrefutable health beneﬁts. For people
with knee osteoarthritis (OA), pain is a well-known cause of functional
limitation in people with knee (OA), however it is unclear whether it is
also responsible for a reduction in physical activity behaviors. Anec-
dotally, pain is thought to be responsible for less physical activity. We
will review the literature investigating whether knee OA-related pain is
in fact a risk factor for less physical activity. As well, we will investigate
whether physical activity is responsible for changes in pain.
Methods: We will summarize studies of objectively measured physical
activity among people with knee OA from well-established cohort
studies. We will also review the association of physical activity with
knee pain and function from clinical intervention trials and observa-
tional studies among people with knee OA.
Results: Physical activity guidelines, i.e., participation in at least 150
minutes of moderate to vigorous physical activity (MVPA), was met by
12.9% of men and 7.7% of women from the Osteoarthritis initiative.
However, a similarly low proportion met guidelines from the National
Health and Nutrition Examination Survey. Furthermore, a similar pro-
portion of people with and without knee pain met guidelines from daily
walking from the Multicenter Osteoarthritis (MOST) study. These data
suggest the presence of knee painmay not fully account for low levels of
physical activity in knee OA. Clinical trials incorporating physical
activity interventions, such as aerobic walking, reduce knee pain. We
have previously reported a strong association between walking at least
6,000 steps/day and the prevention of functional limitation 2 years later
in the MOST study.
Conclusions: Knee pain alone may not lead to a reduction in physical
activity among people with knee OA. However, the beneﬁts of adopting
a physically active lifestyle include reducing existing knee pain and
preventing the development of functional limitation in knee OA.
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THE AGING PROCESS AND EPIGENETICS: RELATIONSHIP WITH OA
L. Reynard. Inst. of Cellular Med., Newcastle Univ., Newcastle upon Tyne,
United Kingdom
Purpose: The term ‘epigenetics’ refers to heritable changes in gene
expression or phenotype that occur without changes to the underlying
DNA sequence. There are three mechanisms of epigenetic gene regu-
lation; DNA methylation, post-translational modiﬁcations of histone
proteins, and non-coding RNAs (ncRNAs) such as microRNAs. They
regulate gene expression either by affecting gene transcription (DNA
methylation, histone modiﬁcations and some ncRNAs) or by acting
post-transcriptionally, leading to changes in the levels of the encoded
protein (e.g. microRNAs). Epigenetic patterns are both plastic, especially
during development and cell differentiation when they undergo
dynamic changes, and stable, allowing cellular identify to be main-
tained during mitotic cell divisions. Furthermore, epigenetic changes
occur in response to environmental factors including diet, exercise and
smoking, and during aging, leading to the suggestion that a possible
mechanism for the late onset of common human diseases is the age-
related loss of normal epigenetic control. Several studies have indicated
that epigenetic changes contribute to the alterations in gene expression
and phenotype observed during aging and in OA. The majority of these
studies have been performed in cartilage due to its lack of cell hetero-
geneity, and in the case of DNA methylation, have concentrated on the
promoter regions of genes that are dysregulated in OA. In this talk, I will
begin by giving an overview of the age- and OA-related epigenetic
changes observed in musculoskeletal tissues. I will then present the
ﬁndings from our recent genome-wide methylation analysis of aged
and osteoarthritic cartilage. I will ﬁnish by discussing areas for future
research into epigenetics and aging of the musculoskeletal system, and
in particular, given that OA is a disease of the whole joint, the potential
to extend these analyses to other joint tissues.I-5
UPDATE ON CRYSTALS AND OA
A.K. Rosenthal. Med. Coll. of Wisconsin, Milwaukee, WI, USA
Calcium-containing crystals including calcium pyrophosphate ( CPP)
and basic calcium phosphate (BCP) crystals are common components of
osteoarthritic (OA) synovial ﬂuid. Similarly, histologic examination of
tissue from unselected patients undergoing total joint replacement for
OA demonstrate BCP crystal deposition in 100% and CPP crystals in 20-
30%. Despite their high prevalence, the role of these crystals in OA
remains poorly understood.
New ﬁndings relevant to our understanding of crystal formation and
the pathogenesis of OA will be discussed. For example, the role of
extracellular ATP in OA and crystal formation, the critical participation
of ANK protein in cartilage calciﬁcation, and some novel work on for-
mation and release of articular cartilage vesicles will be presented. The
impact of these studies on available and emerging management strat-
egies will be addressed. The cause/effect relationship between OA and
calcium-containing crystal deposition is complex and multifactorial.
While many risk factors and some etiologic factors are shared, it is clear
that calcium-containing crystals contribute to cartilage damage in OA.
CPP crystals produce articular inﬂammation likely by stimulating
components of the innate immune system. The inﬂammatory potential
of BCP crystals as well as the mechanisms involved are much less well
understood. These pathways will be discussed in the context of the
increasing evidence that inﬂammatory processes play a critical role in
OA. BCP and CPP crystals also produce non-inﬂammatory tissue damage
by directly interacting with synovial cells and chondrocytes, and their
presence causes alterations in tissue mechanics which can contribute to
joint dysfunction and pain.
Improved recognition of these crystals in the clinical setting and better
appreciation of their etiological role in OA will ultimately result in
better treatments for all patients with degenerative arthritis.
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CYTOKINE CROSSTALK IN INFLAMMATORY AND MECHANICAL
STRESS MECHANISMS IN OSTEOARTHRITIS
M.B. Goldring y,z. yHosp. for Special Surgery, New York, NY, USA; zWeill
Cornell Med. Coll., New York, NY, USA
Osteoarthritis (OA) is a whole joint disease, in which thinning and loss
of cartilage is a critical determinant in OA progression. The disruption of
cartilage homeostasis due to multiple potential causes, related to aging,
genetic susceptibility, trauma, or disordered metabolism, is associated
with profound phenotypic modiﬁcations of chondrocytes. Early
changes involve disruption of the pericellular matrix through signaling
events mediated by chondrocyte receptors such as discoidin domain
receptor-2 (DDR-2). Studies in my laboratory address the mechanisms
of gene regulation by which stress- and inﬂammation-induced signals
induce expression of matrix metalloproteinase 13 (MMP-13), the piv-
otal collagen-degrading proteinase that marks OA progression, as well
as other catabolic and inﬂammatory responses in cartilage and other
joint tissues. Common mediators of these processes, which are also
involved in mechanotransduction in OA cartilage, include IKKs and
MAPKs. These pathways converge on transcriptional regulation by NF-
kB, Elf3, C/EBPb, Runx2, and hypoxia-inducible factor (HIF) 2a. The
IKKb-driven canonical NF-kB signaling pathway coordinates mechan-
ical, inﬂammatory, and oxidative stress-activated events leading normal
chondrocytes to become activated, promoting catabolic events. IKKa,
the non-canonical IKK that also participates in canonical signaling,
functions as a positive mediator chondrocyte differentiation to a
hypertrophic-like phenotype independent of its kinase activity. NF-kB
signaling is among the gene signatures in post-traumatic OA and aging
models and human OA chondrocytes exhibit prominent epigenomic
alterations, such as de-methylation of CpG sites in the promoters of
MMP13, IL1B, and other key genes. These alterations lead to de-regu-
lated gene expression, exacerbated, and sustained NF-kB activation and
production of proteinases and inﬂammatory mediators, all of which can
be modeled in vitro by IL-1b stimulation. We are currently proﬁling
temporal and spatial changes in gene expression and microRNAs over
the course of disease initiation and progression in mouse models of OA
using novel mouse strains with inducible, cartilage-speciﬁc deletion of
IKKa and IKKb, in addition to the Runx2þ/- mouse, which is protected
from OA, and the Col11a1þ/- chondrodysplasia mouse that develops
accelerated OAwith aging. We have also generated novel mouse strains
Abstracts / Osteoarthritis and Cartilage 23 (2015) A17eA25 A19in which the NF-kB-dependent ETS transcription factor, Elf3, is either
knocked out speciﬁcally in cartilage (Col2a1Cre;Elf3ﬂ/ﬂ) or overex-
pressed in cartilage and synovium (ComptTA;TRE-Elf3) to analyze the
impact on OA initiation and progression. In this session, I will address
the in vitro and in vitro models that we use in our research to under-
stand how these mediators play pivotal roles in OA disease by coordi-
nating a complex, multilayered signaling network.
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PLACEBO RESPONSE: IT'S ROLE IN OA RESEARCH AND CLINICAL
PRACTICE
P. Dieppe. Univ. of Exeter, Exeter, United Kingdom
Purpose: To review recent research on placebo and nocebo of relevance
to osteoarthritis.
Methods: Literature reviews, psycho-physiological experiments,
recordings of patient-practitioner interactions, and qualitative inter-
views with people with pain and osteoarthritis.
Results: The placebo response is a purely artiﬁcial phenomenon: it is
the response seen to an inert, sham or dummy therapy administered as
a comparator to a tested intervention in the unreal, experimental
context of a clinical trial. It is poorly understood, and sometimes con-
sidered a ‘nuisance’ to trialists and those at the forefront of the evidence
based medicine movement. But it provides us with insights into one of
the most important phenomena in clinical medicine: the ability of
people to get symptomatically better without the use of any speciﬁc
intervention.
In trials of interventions designed to help people with osteoarthritis
(OA) we see large placebo responses, particularly for symptoms such as
pain and stiffness. In a systematic review/meta-analysis, the effect size
of placebos for OA symptoms was found to be around 0.5, which is
greater than that of many accepted interventions used. Injections have a
greater placebo effect than tablets, and trials using sham surgery have
shown that several surgical procedures used for people with OA, such as
arthroscopic washouts of the knee, are not superior to the sham
intervention. Clearly, a better understanding of what factors are
involved in producing a large placebo effect would help people trying to
assess new interventions for OA.
The placebo effect is seen in response to many different types of
intervention, and the symptoms (but probably not the pathology) of
many different diseases can respond to placebos used in clinical trials.
Some of the best research has come fromwork on models of acute pain,
on Parkinson’s disease and depression, and these disorders may be
better models than OA for the exploration of the psychological and
neurological mechanisms involved. Early research on mechanisms
concentrated on psychological factors: expectations and conditioning
were considered the key mechanisms, with other factors such as
anxiety (which can reduce the response) also involved. More recently
functional neuro-imaging and neurophysiological studies have come to
dominate the literature. It would seem that placebo analgesia may
involve activation of the descending inhibitory pathways of pain con-
trol, and be mediated, in part, by intrinsic opiods; however, there is
clearly heterogeneity within mechanisms as well as the clinical
responses. Other neurological theories have been postulated, including
activation of the polyvagal system and functional connectivity.
Clinicians trying to help people with OA need to consider all aspects of
the context in which they deliver care to people with OA, in order to
maximise the beneﬁt that can accrue from the non-speciﬁc (placebo)
aspects of their interventions. We have self-healing potential, and what
we discuss as a ‘placebo effect’ is a part of the even bigger, more
important phenomenon of activated self-healing of body mind and
spirit.
Attention has recently been re-drawn to the power of the placebo’s ‘evil
twin’ - the nocebo effect. It is clear that negative expectations and
anxiety can result in pain getting worse instead of better, and a recent
research report entitled ‘bad is more powerful than good’ cites the
psychological evidence that suggests that we are more susceptible to
negative inﬂuences on our bodies and minds than to positive ones.
Conclusions: Context (placebo) effects are a major component of the
symptomatic response of people with OA to conventional interventions.
However, many patient-practitioner interactions inadvertently result in
the opposite effect (a nocebo response). We need to learn how to use
the former to the advantage of our patients, and avoid the latter.I-8
ENDOGENOUS MECHANISMS AND PATHWAYS OF CARTILAGE
HEALING
F. Beier. Western Univ., London, ON, Canada
Cartilage degeneration is the major hallmark of osteoarthritis. The
repair and renewal capacity of articular cartilage has long been thought
to be extremely limited. However, recent evidence for endogenous
cartilage repair has cast doubt on this dogma. I will review recent lit-
erature on this process, the molecular mechanisms involved, and
potential factors inﬂuencing renewal capacity (age, genetic background
etc.). I will also focus on the pathways regulating development of
articular cartilage, with the underlying working model that manipu-
lation of these pathways is a promising strategy to promote growth and
repair of articular cartilage. In this context I will present our recent data
showing that cartilage-speciﬁc inactivation of the signaling molecule
Mig-6 in mice results in marked increases in articular cartilage thick-
ness and articular chondrocyte proliferation.
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CLINICAL DEFINITIONS OF EARLY OA: IMPLICATIONS FOR
PREVENTION
G. Peat. Keele Univ., Keele, United Kingdom
Advances in imaging and other biomarkers have been actively
extending knowledge on molecular and pre-radiographic stages of
osteoarthritis pathology. However, the interpretation of biomarkers
typically demands knowledge of their relationship to clinically impor-
tant states or events, either at the time of biomarker acquisition or in
the future. Therefore within this expanding view of the natural history
of osteoarthritis lies a set of complex challenges. Among these chal-
lenges are (i) to reﬂect on how and at what stage in the natural history
of the condition patients currently present to health services; (ii) to
elucidate the nature and timing of emergent signs and symptoms in
relation to biomarker-deﬁned disease states and their signiﬁcance for
future clinically important states and events.
Currently, if detection of OA is assumed to be the point of recorded
clinical diagnosis of OA in routine primary care, electronic health record
(EHR) database studies suggest that this occurs relatively late in the
pathological process, and varies substantially between individual
practitioners. This does not, however, fully capture when symptomatic
osteoarthritis ﬁrst presents nor when management begins. An unclear
proportion of osteoarthritis diagnoses are preceded by prior con-
sultations for joint symptoms labelled as non-speciﬁc problems. How-
ever, the longitudinal pattern of these prior consultations together with
other risk factor information held within the EHR may be exploited for
risk prediction algorithms. Qualitative studies of the osteoarthritis
consultation in primary care provide additional examples of symptoms
of OA presented as mere ‘fragments’ in the doctor-patient interaction or
as ‘door handle’ problems that remain off the record but which in
theory present opportunities for earlier recognition andmanagement of
OA. A critical issue is which of these presenting signs and symptoms are
of real prognostic signiﬁcance.
Findings from a series of population-based prospective observational
cohort studies provide evidence on several symptoms and signs
occurring in a pre-radiographic stage that can precede, and are asso-
ciated with an increased risk of, the incidence of frank structural
abnormality on plain radiographs. In recent analyses a possible pro-
dromal phase of increasing likelihood of symptoms among cases
developing incident radiographic OA has been described. However, the
ability of these early signs and symptoms to consistently identify
individuals with a high absolute risk of future clinically important states
and events cannot be assumed. A single irreversible transition into
progressive OA may not be the norm and extended periods of apparent
non-progressive symptoms and functional limitation have been repor-
ted. Furthermore, it remains possible that the majority of cases of
progressive or ultimately severely disabling cases arise not from the few
individuals classed as high risk but from the many classed as low-
medium risk (Rose’s prevention paradox).
